Abstract：Objective: To study the role of zoledronic acid in the treatment of osteoporosis and to explore its effect on bone metabolism. Methods: One hundred and sixty patients diagnosed as primary osteoporosis in our hospital from January 2017 to March 2019 were randomly divided into treatment group (80 cases) and control group (80 cases). Patients in the control group were giving oral Calcium D tablets daily for 12 months. Patients in the treatment group were given intravenous zoledronic acid (Zometa). ANOVA with repeated measurement data was used to compare the pain scores, bone mineral density and bone metabolism related indexes of the two groups of patients before and one year after treatment. Results: The differences in bone pain scores, bone mineral density, and other bone metabolism indexes between the two groups were statistically significant (P<0.001), and the differences before and after treatment were statistically significant (P<0.001). There is an interaction effect between the groups and time (P<0.001). The differences between the two groups before and after treatment were different, and the treatment group has a larger change (P<0.001). There was no statistically significant difference in blood calcium (Ca), blood phosphorus (P), and BGP levels between the two groups of patients, nor was the difference between before and after treatment, and there was no interaction; the difference in BALP between the two groups was statistically significant ( P<0.001), the differences in BALP levels before and after treatment were statistically significant (P<0.001), and there was an interaction between different groups and time (P<0.001), and the differences between the two groups before and after treatment were different. The group changed more significantly (P<0.001). The incidence of the control group was 7.50%, and the incidence of the treatment group was 8.75%. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Zoledronic acid can effectively improve bone pain and bone metabolism related indicators, reduce bone resorption, increase bone density, less adverse reactions, and better patient compliance.
刘海龙, 王志刚, 龚箭. 唑来膦酸对骨质疏松症患者骨痛评分及骨代谢指标的影响研究[J]. 河北医学, 2021, 27(1): 146-149.
LIU Hailong, WANG Zhigang, GONG Jian. Effect of Zoledronic Acid Injection on Bone Pain Score and Bone Metabolism Index in Patients with Osteoporosis. HeBei Med, 2021, 27(1): 146-149.
2021, Vol. 27 
冀公网安备13080202000677号